140 related articles for article (PubMed ID: 36423900)
1. Examining fentanyl and its analogues in the unregulated drug supply of British Columbia, Canada using drug checking technologies.
Crepeault H; Socias ME; Tobias S; Lysyshyn M; Custance A; Shapiro A; Ti L
Drug Alcohol Rev; 2023 Mar; 42(3):538-543. PubMed ID: 36423900
[TBL] [Abstract][Full Text] [Related]
2. An outbreak of novel psychoactive substance benzodiazepines in the unregulated drug supply: Preliminary results from a community drug checking program using point-of-care and confirmatory methods.
Laing MK; Ti L; Marmel A; Tobias S; Shapiro AM; Laing R; Lysyshyn M; Socías ME
Int J Drug Policy; 2021 Jul; 93():103169. PubMed ID: 33627302
[TBL] [Abstract][Full Text] [Related]
3. Initial results of a drug checking pilot program to detect fentanyl adulteration in a Canadian setting.
Tupper KW; McCrae K; Garber I; Lysyshyn M; Wood E
Drug Alcohol Depend; 2018 Sep; 190():242-245. PubMed ID: 30064061
[TBL] [Abstract][Full Text] [Related]
4. Assessing the limit of detection of Fourier-transform infrared spectroscopy and immunoassay strips for fentanyl in a real-world setting.
McCrae K; Tobias S; Grant C; Lysyshyn M; Laing R; Wood E; Ti L
Drug Alcohol Rev; 2020 Jan; 39(1):98-102. PubMed ID: 31746056
[TBL] [Abstract][Full Text] [Related]
5. Detecting fentanyl using point-of-care drug checking technologies: A validation study.
Ti L; Tobias S; Lysyshyn M; Laing R; Nosova E; Choi J; Arredondo J; McCrae K; Tupper K; Wood E
Drug Alcohol Depend; 2020 Jul; 212():108006. PubMed ID: 32438280
[TBL] [Abstract][Full Text] [Related]
6. Drug checking identifies counterfeit alprazolam tablets.
Tobias S; Shapiro AM; Grant CJ; Patel P; Lysyshyn M; Ti L
Drug Alcohol Depend; 2021 Jan; 218():108300. PubMed ID: 33127185
[TBL] [Abstract][Full Text] [Related]
7. A new quantitative drug checking technology for harm reduction: Pilot study in Vancouver, Canada using paper spray mass spectrometry.
Borden SA; Saatchi A; Vandergrift GW; Palaty J; Lysyshyn M; Gill CG
Drug Alcohol Rev; 2022 Feb; 41(2):410-418. PubMed ID: 34347332
[TBL] [Abstract][Full Text] [Related]
8. Responding to changes in the unregulated drug supply: the need for a dynamic approach to drug checking technologies.
Bhuiyan I; Tobias S; Ti L
Am J Drug Alcohol Abuse; 2023 Nov; 49(6):685-690. PubMed ID: 37506334
[TBL] [Abstract][Full Text] [Related]
9. Take-home drug checking as a novel harm reduction strategy in British Columbia, Canada.
Klaire S; Janssen RM; Olson K; Bridgeman J; Korol EE; Chu T; Ghafari C; Sabeti S; Buxton JA; Lysyshyn M
Int J Drug Policy; 2022 Aug; 106():103741. PubMed ID: 35671687
[TBL] [Abstract][Full Text] [Related]
10. Motivators of and barriers to drug checking engagement in British Columbia, Canada: Findings from a cross-sectional study.
Tobias S; Ferguson M; Palis H; Burmeister C; McDougall J; Liu L; Graham B; Ti L; Buxton JA
Int J Drug Policy; 2024 Jan; 123():104290. PubMed ID: 38101275
[TBL] [Abstract][Full Text] [Related]
11. Detection of synthetic cannabinoid adulteration in the unregulated drug supply in three Canadian settings.
Ti L; Tobias S; Maghsoudi N; Milloy MJ; McDonald K; Shapiro A; Beriault D; Stefan C; Lysyshyn M; Werb D
Drug Alcohol Rev; 2021 May; 40(4):580-585. PubMed ID: 33354869
[TBL] [Abstract][Full Text] [Related]
12. Development of a neural network model to predict the presence of fentanyl in community drug samples.
Ti L; Grant CJ; Tobias S; Hore DK; Laing R; Marshall BDL
PLoS One; 2023; 18(7):e0288656. PubMed ID: 37440523
[TBL] [Abstract][Full Text] [Related]
13. Portable gas chromatography-mass spectrometry in drug checking: Detection of carfentanil and etizolam in expected opioid samples.
Gozdzialski L; Aasen J; Larnder A; Ramsay M; Borden SA; Saatchi A; Gill CG; Wallace B; Hore DK
Int J Drug Policy; 2021 Nov; 97():103409. PubMed ID: 34392112
[TBL] [Abstract][Full Text] [Related]
14. Drug checking as a potential strategic overdose response in the fentanyl era.
Laing MK; Tupper KW; Fairbairn N
Int J Drug Policy; 2018 Dec; 62():59-66. PubMed ID: 30359874
[TBL] [Abstract][Full Text] [Related]
15. Costing analysis of a point-of-care drug checking program in Rhode Island.
Cepeda JA; Thompson E; Ujeneza M; Tardif J; Walsh T; Morales A; Rosen JG; Green TC; Park JN
Drug Alcohol Depend; 2023 Dec; 253():111028. PubMed ID: 38000322
[TBL] [Abstract][Full Text] [Related]
16. Results from a mobile drug checking pilot program using three technologies in Chicago, IL, USA.
Karch L; Tobias S; Schmidt C; Doe-Simkins M; Carter N; Salisbury-Afshar E; Carlberg-Racich S
Drug Alcohol Depend; 2021 Nov; 228():108976. PubMed ID: 34536717
[TBL] [Abstract][Full Text] [Related]
17. Drug checking services as a surveillance tool for clinical laboratories: Examining trends in the unregulated fentanyl supply.
Delaney SR; Konforte D; Stefan C; Palaty J; Sun D; McDonald K; Thompson H; Werb D; Beriault DR
Clin Biochem; 2023 Jan; 111():11-16. PubMed ID: 36379241
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a fentanyl drug checking service for clients of a supervised injection facility, Vancouver, Canada.
Karamouzian M; Dohoo C; Forsting S; McNeil R; Kerr T; Lysyshyn M
Harm Reduct J; 2018 Sep; 15(1):46. PubMed ID: 30200991
[TBL] [Abstract][Full Text] [Related]
19. Variability in the unregulated opioid market in the context of extreme rates of overdose.
Larnder A; Saatchi A; Borden SA; Moa B; Gill CG; Wallace B; Hore D
Drug Alcohol Depend; 2022 Jun; 235():109427. PubMed ID: 35405459
[TBL] [Abstract][Full Text] [Related]
20. A qualitative assessment of key considerations for drug checking service implementation.
Grace Rose C; Pickard AS; Kulbokas V; Hoferka S; Friedman K; Epstein J; Lee TA
Harm Reduct J; 2023 Oct; 20(1):151. PubMed ID: 37848875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
